Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Responds To Changing Market; Streamlining “Not A Fire Sale” – Lafley

This article was originally published in The Tan Sheet

Executive Summary

Shareholders at P&G’s annual meeting sought insight into the firm’s plan to divest up to half of its brands over the next two years, but CEO A.G. Lafley offered no details while asserting the soundness of the strategy in terms of focusing the company and reducing costs.

You may also be interested in...



Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

Avadim Adamant Its Support For Homeopathic Topical Ad Claims Meets FTC Standards

Avadim Health could get FTC scrutiny after it declines to comply with two findings by an industry self-regulation group to discontinue 26 claims for its Theraworx Relief homeopathic products. It says the analysis “misapplied the well-recognized standards of substantiation” established by FTC. 

Pandemic Driving Stress In Consumers? DuPont Has A Probiotic Strain For That

HOWARU Calm contains probiotic strain Lpc-37 (L. paracasei) and can be added to supplements or formulated into new products, says DuPont Nutrition & Biosciences. It reports that 65% of adults worldwide are experiencing some daily stress.

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel